Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Axsome Therapeutics Inc.

    NASDAQ: AXSM · Real-Time Price · USD
    102.69
    -1.01 (-0.97%)
    At close: Jun 26, 2025, 3:59 PM
    104.00
    1.28%
    After-hours: Jun 26, 2025, 06:31 PM EDT

    Axsome Therapeutics Statistics

    Share Statistics

    Axsome Therapeutics has 49.24M shares outstanding. The number of shares has increased by 2.67% in one year.

    Shares Outstanding

    n/a
    		 49.24M

    Shares Change (YoY)

    n/a
    		 2.67%

    Shares Change (QoQ)

    n/a
    		 0.63%

    Owned by Institutions (%)

    n/a
    		 77.29%

    Shares Floating

    n/a
    		 40.45M

    Failed to Deliver (FTD) Shares

    n/a
    		 44

    FTD / Avg. Volume

    n/a
    		 0.01%

    Short Selling Information

    The latest short interest is 3.88M, so 7.96% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 3.88M

    Short % of Shares Out

    n/a
    		 7.96%

    Short % of Float

    n/a
    		 9.53%

    Short Ratio (days to cover)

    n/a
    		 7.8

    Valuation Ratios

    The PE ratio is -14.11 and the forward PE ratio is 64.31. Axsome Therapeutics's PEG ratio is -1.03.

    PE Ratio

    n/a
    		 -14.11

    Forward PE

    n/a
    		 64.31

    PS Ratio

    n/a
    		 10.51

    Forward PS

    n/a
    		 1.9

    PB Ratio

    n/a
    		 71.1

    P/FCF Ratio

    n/a
    		 -31.5

    PEG Ratio

    n/a
    		 -1.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Axsome Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.11, with a Debt / Equity ratio of 3.38.

    Current Ratio

    n/a
    		 2.11

    Quick Ratio

    n/a
    		 2.04

    Debt / Equity

    n/a
    		 3.38

    Debt / EBITDA

    n/a
    		 -0.71

    Debt / FCF

    n/a
    		 -1.5

    Interest Coverage

    n/a
    		 -42.71

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $541,703.65

    Profits Per Employee

    n/a
    		 $-403,393.26

    Employee Count

    n/a
    		 712

    Asset Turnover

    n/a
    		 0.68

    Inventory Turnover

    n/a
    		 2.12

    Taxes

    Income Tax

    n/a
    		 85K

    Effective Tax Rate

    n/a
    		 -0.03%

    Stock Price Statistics

    The stock price has increased by 28.22% in the last 52 weeks. The beta is 0.47, so Axsome Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.47

    52-Week Price Change

    n/a
    		 28.22%

    50-Day Moving Average

    n/a
    		 106.68

    200-Day Moving Average

    n/a
    		 102.74

    Relative Strength Index (RSI)

    n/a
    		 43.11

    Average Volume (20 Days)

    n/a
    		 729,285

    Income Statement

    In the last 12 months, Axsome Therapeutics had revenue of 385.69M and earned -287.22M in profits. Earnings per share was -5.99.

    Revenue

    n/a
    		 385.69M

    Gross Profit

    n/a
    		 352.39M

    Operating Income

    n/a
    		 -280.56M

    Net Income

    n/a
    		 -287.22M

    EBITDA

    n/a
    		 -272.6M

    EBIT

    n/a
    		 -280.56M

    Earnings Per Share (EPS)

    n/a
    		 -5.99
    Full Income Statement

    Balance Sheet

    The company has 315.35M in cash and 192.96M in debt, giving a net cash position of 122.4M.

    Cash & Cash Equivalents

    n/a
    		 315.35M

    Total Debt

    n/a
    		 192.96M

    Net Cash

    n/a
    		 122.4M

    Retained Earnings

    n/a
    		 -1.12B

    Total Assets

    n/a
    		 596.67M

    Working Capital

    n/a
    		 250.72M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -128.41M and capital expenditures -270K, giving a free cash flow of -128.68M.

    Operating Cash Flow

    n/a
    		 -128.41M

    Capital Expenditures

    n/a
    		 -270K

    Free Cash Flow

    n/a
    		 -128.68M

    FCF Per Share

    n/a
    		 -2.69
    Full Cash Flow Statement

    Margins

    Gross margin is 91.37%, with operating and profit margins of -72.74% and -74.47%.

    Gross Margin

    n/a
    		 91.37%

    Operating Margin

    n/a
    		 -72.74%

    Pretax Margin

    n/a
    		 -74.45%

    Profit Margin

    n/a
    		 -74.47%

    EBITDA Margin

    n/a
    		 -70.68%

    EBIT Margin

    n/a
    		 -72.74%

    FCF Margin

    n/a
    		 -33.36%

    Dividends & Yields

    AXSM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for AXSM is $178, which is 73.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $178

    Price Target Difference

    n/a
    		 73.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 15
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 2.52

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist